Novo Nordisk announced that Rybelsus, a once-a-day semaglutide pill, received a new Health Canada authorization, with all other GLP-1 drugs available in Canada to date being injectables
adults in January 2026 via Pollfish, an online survey platform
Diabetes (2020) 69:161123
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist currently in Phase 3 trials
Fortunately, a range of specialized cosmetic procedures can rejuvenate your features, restoring confidence and a youthful look
Dial 208-732-2020 today to arrange your initial consultation and make the first move towards a more vibrant and confident you